Number of isolation facilities, existence of High Level Isolation Units, and isolation beds for highly infectious patients per participating country.

<p>(#): Numbers in brackets indicate the amount of High Level Isolation Units per country, if existing. (*): Total population calculated on the basis of Eurostat <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0100401#pone.0100401-European3" target="_blank">[30]</a>. (§): Facilities enrolled are located in the Catalonia region, only.</p><p>Number of isolation facilities, existence of High Level Isolation Units, and isolation beds for highly infectious patients per participating country.</p

Access to specifically trained personnel.

<p>Number of facilities enrolled with access to specifically trained personnel (overall response n = 48/48). Access to Infectious Disease and Intensive Care doctors or nurses is provided in the majority of facilities, but specifically trained personnel for paediatric patients is rarely available.</p

Access to and location of Intensive Care beds for HID patients.

<p>Number of facilities enrolled with Intensive Care (IC) capacity and location of IC beds (overall response n = 48/48). 33 facilities provide IC beds within the isolation area, and 12 in designated rooms on standard IC wards.</p

Demographic and clinical features at enrolment.

<p>Demographic and clinical features at enrolment.</p

CONSORT Flow Diagram.

<p>Consort diagram of patients eligible, recruited, numbers followed up and included in analysis.</p

Treatment and clinical progression during admission.

<p>Treatment and clinical progression during admission.</p

Patient screening and enrolment.

<p>*One patient did not give consent. One patient was not competent to give consent, and a suitable proxy to provide consent could not be identified within inclusion time limits. **Two patients who died within 48 h of admission were excluded from the primary outcome analysis, as specified in the protocol.</p

Box and whisker plot of vital signs in TKM-130803 recipients, before, during, and after TKM-130803 infusions.

<p>Heart rate, respiratory rate, mean arterial blood pressure, and tympanic temperature in patients administered TKM-130803 at the following time points: immediately prior to TKM-130803 infusion (PRE), during the infusion, immediately at the end of the infusion (END), and at 1, 2, 4, and 8 h after the end of the infusion. The middle line shows the median value, the box shows the interquartile range, and the whiskers spread from the lower to the upper adjacent values. Outside values, that is, observations that are larger/smaller than the upper/lower adjacent values, are shown as circles.</p